Fintel reports that on December 3, 2025, Morgan Stanley downgraded their outlook for Regeneron Pharmaceuticals (NasdaqGS:REGN ...
Morgan Stanley has downgraded Regeneron Pharmaceuticals ( REGN) to equal-weight from overweight saying that the stock is fairly valued. The bank maintained its price target of $767 (~3% upside based ...
Great. Good morning, everybody. I'm Terence Flynn, Morgan Stanley's U.S. biopharma analyst, and I'm very pleased to be hosting Regeneron to kick off our 23rd Annual Global Healthcare Conference this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback